香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 公告 復星高科 截至 2025 年 9 月 30 日止九個月之 主要財務數據 上海復星高科技（ 集團 ）有限 公 司（（「復星高科 」），復星 國際 有 限公 司（「本 公 司 」）之 附 屬公 司 ）在中 國 銀行 間 債券 市場 發 行超 短 期融 資券、短期融資券 和資 產擔保債務融資工具 以及在上海證券交易所發行 高成長公司債券 ， 根 據 中國相 關規定，復 星高科於 2025 年 10 月 31 日發佈其 2025 年 第 三 季度 報 告（「該報告 」）。 單位：千元 幣種：人民幣 | | 本報告期末 | 上年度末 | 本報告期末比 上年度末增減 (%) | | --- | --- | --- | --- | | 總資產 | 405,025,460 | 404,566,629 | 0.1 | | 歸屬於母公司股東之權益 | 89,829,885 | 91,893,083 | (2.2) | ...

公告 豫園股份 截至 2025 年 9 月 30 日止九個月之 主要財務數據 於 2025 年 10 月 30 日， 上 海豫 園 旅 遊商 城 （集 團 ）股 份有 限 公司 （「 豫 園 股 份 」）， 復星 國 際 有限 公 司（「 本公司 」） 之附 屬 公司 ， 其 A 股 於 上海 證 券 交易 所 上市 及 買賣（ 股份 代 號：600655））刊發其 2025 年第 三季 度 報告（「該 報 告 」）。 本公 司 之董 事 會（「 董事會 」）謹 請 本公 司股 東 及公 眾 投資 者留 意 以下 有 關該 報告 所 載豫 園 股份 截至 2025 年 9 月 30 日止 三 個月 （「本 報 告 期 」）及 九個 月未 經 審計 之 主要 財務 數 據： 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | 本報告期末 | 上年度末 | 本報告期末比上 年度末增減 1 (%) | | --- | --- | --- | --- | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 復星國際有限公司 董事長 郭廣昌 2025年10月23日舉行之股東特別大會投票表決結果 復星 國 際有 限 公司（「 本公司 」）於2025年10月 23日（ 星 期 四）上 午十 時 正 假 座 中 國 上 海 市 黃 浦 區 中 山 東 二 路 600號 外 灘 金 融 中 心 S1幢 39樓 舉 行 之 股 東特 別 大會（「股東特別大會 」）上，股 東特 別 大會 主 席要 求就 載 於 2025年 9月 25日 股 東 特 別 大 會 通 告 （「 該通告 」） 內 提 出 的 決 議 案 以 投 票 方 式 進 行 表決。除文 義 另有 所指 外，本 公 告所 使用 之 詞彙 與 該通 告及 本 公司 日 期為 2025年9月25日 的 通 函（「該通函 」）所 界 定者 具 有相 同 涵義。股 東特 別 大 會 投票 表 決結 果 如下 ： | | 普 通 決議案 | 有效投票 票 數 | ...

Core Insights - The World Intellectual Property Organization (WIPO) has reported that China has successfully risen to the top ten in the Global Innovation Index, highlighting significant progress in technology research and innovation ecosystem development [1] - The upcoming 20th Central Committee meeting is expected to focus on innovation as a key direction for the 14th Five-Year Plan, increasing market attention on companies' technological innovations and strategies [1] Group 1: Company Performance - Fosun International has demonstrated steady revenue and profit growth driven by its core capabilities in innovation and globalization, with a recommendation to "buy" from multiple brokerages [1][2] - The company has made breakthroughs in innovative drugs, including HLX43, a PD-L1 antibody-drug conjugate currently undergoing clinical trials in several countries, positioning it as a potential effective cancer treatment [2] Group 2: Globalization Strategy - Fosun has built a global research, registration, and marketing capability over the past decade, with its biopharmaceutical products reaching nearly 60 countries and benefiting over 850,000 patients [3] - The company’s core product for breast cancer treatment, Hanquyou, has been approved in over 50 countries, showcasing its global reach [3] Group 3: Technological Innovation - Fosun is embracing AI applications across its business sectors, with significant growth in its tourism segment, where the core area of Yuyuan Mall achieved a GMV of RMB 2.6 billion, a 55% year-on-year increase [3] - In the tourism sector, Fosun's Club Med is enhancing its digital services through AI, providing personalized 24/7 support across multiple countries [4] Group 4: Financial Strength - The company has shown robust financing capabilities and an optimized financial structure, with several brokerages expressing confidence in its financial health [5] - In September, Fosun secured a sustainable syndicated loan of $910 million, setting a record for offshore loans for private enterprises in 2025, reflecting strong market confidence in its future [5]

Core Insights - The World Intellectual Property Organization (WIPO) has reported that China has successfully risen to the top ten in the global innovation index, highlighting significant progress in technology research and innovation ecosystem development [1] - The upcoming 20th Central Committee meeting is expected to focus on innovation as a key direction for the 14th Five-Year Plan, increasing market attention on companies' technological innovations and strategies [1] Group 1: Company Performance - Fosun International has demonstrated steady revenue and profit growth driven by its core capabilities in innovation and globalization, with a positive outlook from multiple securities firms [1][2] - The company has received "buy" or "hold" ratings from various institutions, with target prices ranging from 6.5 to 7.5 HKD [1] Group 2: Innovation and Drug Development - Fosun has made significant advancements in its health sector, with innovative drugs like HLX43, a PD-L1 antibody-drug conjugate, undergoing clinical trials in multiple countries [2] - The company has also achieved breakthroughs with its self-developed targeted drug, Fumainin, which has been approved for rare disease indications, filling treatment gaps in oncology [2] Group 3: Globalization Strategy - Fosun has built a global research, registration, and marketing capability over the past decade, with its biopharmaceutical products reaching nearly 60 countries and benefiting over 850,000 patients [3] - The company has established a leading platform for small molecule innovation and has completed over 800 regulatory applications globally, with more than 600 approvals [3] Group 4: AI and Digital Transformation - Fosun is leveraging AI across various business sectors, enhancing customer experiences in tourism and improving operational efficiency in insurance [4] - The company has partnered with Alibaba Cloud to develop an AI-driven tourism assistant, significantly enhancing customer service capabilities [4] Group 5: Financial Strength and Capital Operations - Fosun has shown robust financing capabilities and an optimized financial structure, with a recent syndicate loan agreement reaching a record high of 9.1 billion USD equivalent [5] - The company is expected to continue optimizing its asset structure following recent interest rate cuts by the Federal Reserve, maintaining financial stability [5]

Core Insights - The tourism industry is transitioning from "sightseeing" to "vacationing," emphasizing the need for high-quality tourism products to meet personalized and high-quality consumer demands [2] - The "14th Five-Year Plan" period is crucial for China to advance from a tourism power to a tourism strong nation, focusing on enhancing the quality of tourism offerings [2] - Fosun Tourism Group aims to create world-class vacation products and align with national tourism development goals [2] Company Overview - Fosun Tourism Group operates nearly 70 resorts and hotels across over 40 countries and regions, generating annual revenue exceeding 19 billion yuan and hosting over 8.6 million guests each year [3] - The company has developed four main product lines: Club Med Global, Club Med China, Super Vacation Zones, and Super Cultural Tourism Malls [3]

Core Viewpoint - China Guo Xin Service Holding Limited is preparing for an IPO on the Hong Kong Stock Exchange, aiming to leverage its established brand and reputation in property management and agency services in Guangdong and Hunan provinces [5][6]. Company Overview - Established in 2006, China Guo Xin Service Group is a comprehensive property management and agency service provider, with a significant presence in Guangdong and Hunan provinces [5]. - The company expanded its geographical reach by acquiring Hunan Zhida Property Management in January 2024 [5]. - As of June 30, 2025, the company managed a total contracted area of 5.9 million square meters across 42 property projects, including 24 residential and 18 non-residential properties [5]. Market Position - China Guo Xin Service Group ranks as the fourth largest market participant in the Greater Bay Area property management and agency services market, holding a market share of 0.08% [5]. - The company is also among the top 50 property management service providers in Hunan province, with a market share of 0.06% [5]. Financial Performance - The company reported revenues of RMB 88.127 million, RMB 115.358 million, RMB 196.005 million, and RMB 89.135 million for the years 2022, 2023, 2024, and the first half of 2025, respectively [11]. - Net profits for the same periods were RMB 20.184 million, RMB 28.077 million, RMB 39.041 million, and RMB 12.202 million [10][11]. - Revenue from properties developed by the controlling shareholder accounted for 100.0%, 99.4%, 73.8%, 70.4%, and 68.7% of total revenue from 2022 to the first half of 2025 [6]. Shareholder Structure - The pre-IPO shareholder structure indicates that Mr. Liang Zanwen, through Guo Xin Holdings, holds 100% of the shares [11]. Management Team - The board of directors consists of 7 members, including 4 executive directors and 3 independent non-executive directors [9].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年9月30日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 復星國際有限公司 | | | | 呈交日期: | 2025年10月3日 | | | | I. 法定/註冊股本變動 不適用 | | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00656 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | | 已發行股份總數 | | | 上月底結存 | | | 8,166,558,124 | | | 0 | | 8,166,558, ...

Transaction Overview - The jewelry fashion group plans to introduce investors for financing, with Bank of China Asset increasing capital by RMB 400 million, acquiring 3.5596% equity in the target company [1] - After the transaction, Fosun International will still indirectly hold 91.03% equity through Yuyuan Shares, maintaining control [1] Valuation Basis - According to an independent valuation report, the net asset valuation of the jewelry fashion group is RMB 9.016 billion, with a pre-investment valuation determined based on a projected net profit of RMB 241 million for the second half of 2024 [2] - The investment arrangement includes a buyback option for external investors after 60 months, with the buyback price calculated at an annualized return of 8% [2] - Institutional investors have a transfer option during a 3-year investment period, which can be extended by 2 years [2] Financial Performance - The jewelry fashion group is projected to have a revenue of RMB 29.996 billion and a net profit of RMB 714 million in 2024; for the first half of 2025, revenue is expected to be RMB 12.899 billion with a net profit of RMB 290 million [3] Significance of Listing Rules - The transaction constitutes a major transaction that has received written approval from the controlling shareholder, Fosun Holdings, and does not require a shareholders' meeting [4] - The funds raised will be used to repay qualified financial institution debts [4] External Investors - A total of 36 investors contributed RMB 770 million through Heze Zhuying [5] - Bank of China Asset increased capital by RMB 600 million, acquiring 5.4059% equity [5] - The total financing scale reached RMB 1.98 billion [5]

Adopted on [▪], 2025 | 1. | DEFINITIONS AND INTERPRETATION | 1 | | --- | --- | --- | | 2. | PURPOSES OF THE SCHEME | 5 | | 3. | CONDITIONS | 6 | | 4. | DURATION | 6 | | 5. | ADMINISTRATION | 6 | | 6. | ELIGIBLE EMPLOYEES | 7 | | 7. | CONDITIONS AND TIMING OF GRANT | 8 | | 8. | GRANT INSTRUMENT AND NOTIFICATION OF GRANT | 9 | | 9. | SOURCES OF RESTRICTED SHARES | 10 | | 10. | PROPOSED ALLOCATION UNDER THE FIRST GRANT | 12 | | 11. VESTING | PERIOD AND VESTING CONDITIONS | 13 | | 12. | VESTING OF RSUS | 17 | | ...